Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

Completed · Phase 1

Conditions studied: Influenza, Gammopathy

In brief

A Pilot Study utilizing high dose trivalent influenza vaccine dose in a booster dosing schedule for patients with monoclonal gammopathies stratified by disease status

Key facts

Study ID

NCT02267733

Run by

Yale University

People needed

51

Starts

2014-10-01

Expected to finish

2015-12-01

Last updated by the study team

2016-08-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Understand and voluntarily sign an informed consent document
• Age >= 18 years at the time of signing the informed consent form
• Diagnosis of any monoclonal gammopathy; Monoclonal Gammopathy of Undetermined Significance (MGUS), asymptomatic/ active multiple myeloma, asymptomatic / active Waldenstrom Macroglobulinemia (WM)

You may not qualify if…

• An serious egg allergy or prior serious adverse reaction to an influenza vaccine
• Use of any other influenza vaccine for the 2014 to 2015 flu season
• Women who are pregnant or plan to become pregnant in the study period

Where it is running

• Yale University — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.